GlassScriptPhysician profile
Sabah Kadhium
NPI 1306836770
$6,466.10
in general payments reported to CMS, 2019-2025
43 companies · $736 in 2025
The $736 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,106 · 2020: $926 · 2021: $1,211 · 2022: $840 · 2023: $1,000 · 2024: $647 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,382.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $843.74 | 2019-2024 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $719.14 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Pfizer INC. | $678.55 | 2019-2025 | |
| Novo Nordisk INC | $484.49 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $445.65 | 2019-2025 | Jardiance, Mounjaro, Kisunla |
| Sunovion Pharmaceuticals INC. | $332.95 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $222.50 | 2020-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $216.49 | 2019-2022 | |
| Abbvie INC. | $204.12 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.92 | 2021-2025 | Jardiance |
| Ucb, INC. | $199.11 | 2023-2024 | Briviact, Nayzilam |
| Amgen INC. | $190.51 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $173.03 | 2019-2024 | Eliquis |
| Sumitomo Pharma America, INC. | $135.68 | 2023 | Gemtesa |
| Lundbeck LLC | $127.81 | 2023-2025 | Rexulti |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabah Kadhium listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.